Abstract:T cell lymphomas acquire mutations that endow them with advantages to endure the immunosuppressive tumor microenvironment. Researchers have now found a way to turn the tables on cancer by using these mutations to develop more effective chimeric antigen receptor (CAR) T cell therapies. In a study published in Nature , the authors created a barcoded library of mutant genes from T cell malignancies and screened CAR T cells in vivo for improved persistence in solid tumors. These data were paired with an in vitro screen of T cell signaling. One of the strongest hits was a gene fusion of CARD11–PIK3R3 that enhances CARD11–BCL10–MALT1 signaling. CARD11–PIK3R3-expressing CAR T cells (and engineered T cell receptor (TCR) T cells) were tested in several tumor models and even relatively low cell numbers were effective against tumors in mice, including some that are ordinarily refractory to immunotherapy. Whether these CAR T cells might be used in humans is dependent on planned clinical trials, but perhaps the bigger advance here is in the strategy applied, one which might lead to further CAR T cell designs tailored for specific cancers. Original reference: Nature 626, 626–634 (2024)

Learning from cancer mutations